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Letters to the EditorTo the Editor:
We appreciate the interest of Dr. Thalheimer and Dr. Burroughs
in our study [1]. It is true that the baseline characteristics of
our patients showed a slightly greater percentage of previous
spontaneous bacterial peritonitis, variceal bleeding, and hepato-
cellular carcinoma in the saline arm, but without signiﬁcant dif-
ferences. We agree that the presence of renal failure in the saline
group could be a confounding factor that might help explain the
differences in survival between both groups. However, the MELD
score, used to predict survival, had no differences in both arms.
The ﬁndings in survival were, as is reﬂected in the article, a
secondary endpoint. The study was not designed to evaluate mor-
tality. Nevertheless, we thought that the results had sufﬁcient
clinical relevance to be highlighted. The development of hepatic
encephalopathy in advanced cirrhosis has been related to a worse
prognosis and high mortality [2]. It is possible that the presence
of hepatic encephalopathy identiﬁes a group of patients that can
beneﬁt from the administration of albumin.
We agree that the hypothesis should be tested in subsequent
studies with an adequate design and optimized sample size to
accomplish this goal. The current study sets the basis for explor-
ing the value of albumin in advanced cirrhosis identiﬁed by the
development of hepatic encephalopathy.
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.Fatigue and liver transplantation in patients
with primary biliary cirrhosis
To the Editor:
We read with great interest the paper of Carbone et al. [1] on fati-
gue in patients with primary biliary cirrhosis (PBC) and the role of
liver transplantation. They performed a prospective, longitudinal
study investigating fatigue in 49 adult cirrhotic patients with PBC
at listing and at 6, 12, and 24 months after transplantation. They
found that fatigue scores, as assessed by means of the PBC-40
questionnaire, improved substantially following transplantation
but remained higher compared to community controls two years
post-transplant [1]. In all, 89% of patients had moderate to severe
fatigue before transplantation, which was also true for 48% and
44% at one and two years post-transplant respectively [1].
We have recently reported that although fatigue improves fol-
lowing transplantation in unselected cirrhotic patients, 37% are
physically fatigued 1 year post-transplant [2], which is in accor-
dance with previous studies [3,4]. In this prospective longitudinal
study [2] no patients with hepatic encephalopathy grade >I were
included as they could not complete the study questionnaires.
Encephalopathy was assessed clinically (West-Haven criteria)
and by means of the number connection tests A and B [2]. We
found that fatigue severity in unselected cirrhotic patients wors-
ened with worsening encephalopathy (from none to minimal and
overt) [2]. Only 12 patients included in this paper had PBC (med-
ian age 54 (interquartile range 39–60); 9 female) and 10 reached
1 year post-transplant (1 patient died on the transplant list and
another during the ﬁrst post-transplant year). Fatigue was
assessed by means of the fatigue impact scale, a 40-item ques-
tionnaire, which has been validated in PBC [5]. Fatigue data from
these patients (not reported separately in the initial report) in
comparison to non-PBC cirrhotic patients are shown in Table 1.
Fatigue scores across all domains did not differ signiﬁcantly
between the two groups neither pre- nor post-transplant
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(Table 1). All domain and total fatigue scores improved in both
groups at 1 year post-transplant, but in the PBC group, this was
mainly due to an improvement in the cognitive fatigue domain
score (Table 1). Carbone and colleagues also found that the cog-
nitive domain of the PBC-40 improved post-transplant [1], which
may have been due to an improvement in hepatic encephalopa-
thy. Although they identiﬁed two patients with moderate
encephalopathy (both with severe fatigue one of whom improved
post-transplant), there was no formal assessment of (minimal)
hepatic encephalopathy. This is surprising as encephalopathy in
patients with cirrhosis is a well-known cause of lethargy and fati-
gue. It is also unclear whether any patients were excluded due to
inability to ﬁll in the study questionnaire as a result of hepatic
encephalopathy [1]. As the authors argue, fatigue severity may
not be related to non-cirrhotic PBC severity at a group level [1]
but it appears to be related to liver disease severity in cirrhosis
in general [2]. Also, our data showing that improvement in fati-
gue post-transplant in PBC patients was attributed mainly to
improvement in cognitive fatigue, and the fact that the two
patients with moderate encephalopathy in the current study
had severe fatigue with one improving post-transplant [1], indi-
cate that encephalopathy could be an important factor leading
to fatigue at least for some cirrhotic patients with PBC.
In line with our ﬁndings in the whole cirrhotic cohort [1], we
found that physical fatigue scores of PBC patients also improved
but this failed to reach statistical signiﬁcance (Table 1). In all, 5
out of 12 PBC patients (42%) had signiﬁcant physical fatigue
(physical fatigue scores >2 SD of controls) at pretransplant eval-
uation, which was also true in 3/10 (30%) of PBC patients and
37% of all cirrhotic patients [1] at 1 year post-transplant. Two
out of 4 physically fatigued PBC patients pretransplant who sur-
vived 1 year following transplantation continued to be physically
fatigued post-transplant (50%) compared to 46% in the whole
cirrhotic cohort [1]. Out of 6 PBC patients without signiﬁcant
physical fatigue pre-transplant who survived 1 year following
transplantation, 1 (17%) developed signiﬁcant physical fatigue
post-transplant, compared to 22% in the whole cirrhotic cohort
[1]. Thus, persistent fatigue following liver transplantation does
not appear to be characteristic of PBC and a certain proportion
of PBC and non-PBC cirrhotic patients appear to develop physical
fatigue post-transplant [1–4]. The latter suggests that unidenti-
ﬁed transplantation-related factors may be of importance for
post-transplant fatigue in general. It is unclear, in the cohort of
Carbone and colleagues [1] whether any patients developed fatigue
de novo after transplantation.
In conclusion, taken together our ﬁndings and those of Car-
bone and colleagues [1] indicate that fatigue remains a problem
following liver transplantation in cirrhotic patients with PBC as
well as in patients transplanted for other indications. Some
patients appear to develop physical fatigue post-transplant while
persistent fatigue following liver transplantation does not appear
to be characteristic of PBC as it is also noted in patients with cir-
rhosis transplanted for other indications. Hepatic encephalopathy
could be of importance for fatigue in these patients pre-transplant
and it would be important to include assessment of encephalopathy
by appropriate testing in future studies.
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
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Table 1. Fatigue scores at pre-transplant evaluation and 12 months following liver transplantation in patients with cirrhosis due to PBC and those with cirrhosis
without PBC.
Pre-transplant One-year post-transplant
PBC (n = 12) non-PBC (n = 96) p value PBC (n = 10) non-PBC (n = 50) p value
Physical FIS score 18 (15-24) 22 (10-29) 0.434 12 (0-21)a 11 (0-39)e 0.729
Psychosocial FIS score 37 (29-48) 31 (13-48) 0.609 14 (1-31)b 12 (1-23)e 0.817
Cognitive FIS score 19 (7-24) 15 (4-23) 0.609 5 (0-14)c 4 (0-16)e 0.908
Total FIS score 75 (61-93) 65 (29-101) 0.759 40 (1-64)d 30 (2-77)e 0.729
Data are presented as median (interquartile range).
FIS, fatigue impact scale.
The p values of Mann-Whitney tests are reported in the table.
ap = 0.092 vs. pre-transplant.
bp = 0.114 vs. pre-transplant.
cp = 0.021 vs. pre-transplant.
dp = 0.047 vs. pre-transplant.
ep <0.05 vs. pre-transplant (related-samples Wilcoxon signed rank test).
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Reply to: ‘‘Fatigue and liver transplantation
in patients with primary biliary cirrhosis’’
To the Editor:
We would like to thank Kalaitzakis et al. [1] for the comments on
our article on the effect of liver transplantation (LT) on fatigue in
patients with primary biliary cirrhosis (PBC) [2]. They conﬁrm in
an independent PBC cohort that fatigue remains a problem after
LT. They also address some important issues, such as the need for
an accurate assessment of hepatic encephalopathy (HE) before LT
in patients with PBC, and that fatigue may not be speciﬁc to PBC.
Kalaitzakis et al. [1] showed that fatigue improved after LT
although fatigue scores remained higher than in controls from
the general population. Of note, they found that the median fati-
gue impact score (FIS) after LT was 40, which is identical to the
median FIS in a non-transplant PBC cohort, reported by Goldblatt
et al. [3]. In our study [2] fatigue score, assessed using the PBC-40,
was 26 ± 10 at two years after LT, which was lower compared to a
‘non transplant’ PBC control cohort (31 ± 12; p = 0.03); however,
the fatigue score was higher than a ‘normal’ age- and sex-
matched control group (18 ± 6; p <0.0001).
The work of Kalaitzakis et al., along with our data, casts some
light on the pathophysiology of fatigue, as they suggest the
abnormalities that result in fatigue are either irreversible or that
they do not arise in the affected liver. These ﬁndings also are
helpful in identifying the role of transplantation in symptomatic
patients with PBC.
Chronic fatigue is a feature of HE and the relationship
between fatigue and HE in patients with PBC and other chronic
liver conditions is complex and not fully understood. Emerging
data suggest that continued cognitive impairment post-trans-
plant is seen in particularly in patients with recurrent encepha-
lopathy pre-transplant. This suggests that the neuropsychiatric
abnormalities of encephalopathy, as the fatigue of PBC, do not
fully revert post-transplant [4]. Larger, longitudinal studies are
required to address this issue.
In the Birmingham liver unit, HE is routinely assessed using
the Number Connection Test and graded clinically from 0–4 (West
Haven criteria). In our study no patient was excluded because of
overt HE. In the ﬁnal cohort analyzed, only two had clinically evi-
dent HE who had grade 2 HE before LT. In one patient the fatigue
persisted after transplant with the same severity (PBC-40 score of
45 and 46, before and two-years after LT). In the other, the fatigue
improved but remained of moderate severity (falling from 46
before transplant to 30 two-years after LT). Therefore we do not
believe the high fatigue scores before LT were suggestive of HE-
related fatigue. Furthermore, we did not ﬁnd any correlation
between the severity of the liver disease and the severity of the
fatigue, in keeping with previous literature. Minimal HE can only
be determined by a comprehensive neurological assessment of
consciousness, cognitive, and motor function and this has not
been part of our routine pre-transplant assessment.
Kalaitzakis et al. have shown the persistence of fatigue after LT
in those with other indications. However, data from more than
half of the patients was excluded from the ﬁnal analysis. As sug-
gested by Kalaitzakis et al. unidentiﬁed transplantation-related
factors may be relevant for post-transplant fatigue. However, as
shown in Fig. 3 of our paper [2], no patient developed fatigue
de novo after transplantation.
Further studies are needed to establish if the changes
seen here are unique to PBC and to identify the mechanisms
responsible for this symptom, and so develop appropriate
treatments.
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
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